- Design
- Observational study across four biobanks with meta-analysis
- Population
- Over 570,000 participants; IPF diagnosed in 0.6–6.5% per cohort
- Primary outcome
- Association of polygenic risk score with IPF diagnosis and transplant-free survival
- Effect
- Diagnosis odds ratio 2.88 (2.41–3.44); death/transplant hazard ratio 1.23 (1.11–1.35)
Genetic risk for idiopathic pulmonary fibrosis can be summarised into a polygenic risk score, but mostly in curated research cohorts. This study tested the score against routine electronic-record diagnoses across four biobanks totalling over half a million people.
A high-risk score was associated with an IPF diagnosis (odds ratio 2.88, 95% CI 2.41–3.44) and, among those diagnosed, with death or lung transplant (hazard ratio 1.23, 95% CI 1.11–1.35). So the score tracks both who develops IPF and who does worse with it, at biobank scale.
This is a step toward using inherited risk in practice, but not a clinical test yet: the diagnosis odds ratio is modest for individual prediction, the outcome effect smaller still, and the cohorts are largely of European ancestry, which limits transfer to Indian patients. It is a research-stage signal that genetics may eventually refine IPF risk assessment, not a reason to order a score today.
- A high-risk polygenic score was associated with IPF diagnosis (odds ratio 2.88) across biobanks.
- It also tracked with death or lung transplant among those with IPF (hazard ratio 1.23).
- The effects are modest for individual prediction and the cohorts largely European.
- This is research-stage, not a clinical test to order now.
Why it matters
It signals that inherited risk may eventually sharpen who to watch for IPF, while making clear that moment has not arrived.
Don't overread it
Observational biobank associations of modest size in mainly European populations do not establish clinical utility for an individual patient.
The statistics, in plain English
An odds ratio of 2.88 at population level still predicts any one person's risk poorly, and a hazard ratio of 1.23 for outcome is small; useful for research stratification, not individual decisions.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for pulmonology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free